Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia

NCT02694328 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02694328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02694328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 2, 2016
Completion date
November 7, 2018
Enrollment
561 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia